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Abstract 
We are still very limited in management strategies for dementia, and establishing effective disease 
modifying therapies based on amyloid or tau remains elusive. Neuroinflammation has been 
increasingly implicated as a pathological mechanism in dementia and demonstration that it is a key 
event accelerating cognitive or functional decline would inform novel therapeutic approaches, and 
may aid diagnosis. Much research has therefore been done to develop technology capable of 
imaging neuroinflammation in-vivo. The authors performed a systematic search of the literature and 
found twenty-eight studies that used in vivo neuroimaging of one or more markers of 
neuroinflammation on human patients with dementia. The majority of the studies used PET imaging 
of the TSPO microglial marker and found increased neuroinflammation in at least one 
neuroanatomical region in dementia patients, most usually Alzheimer’s disease, relative to controls, 
but the published evidence to date does not indicate whether the regional distribution of 
neuroinflammation differs between dementia types or even whether it is reproducible within a 
single dementia type between individuals. It is less clear that neuroinflammation is increased 
relative to controls in Mild Cognitive Impairment (MCI) than it is for dementia, and therefore it is 
unclear whether neuroinflammation is part of the pathogenesis in early stages of dementia. Despite 
its great potential, this review demonstrates that imaging of neuroinflammation has not thus far 
clearly established brain inflammation as an early pathological event. Further studies are required, 
including those of different dementia subtypes at early stages, and newer, more sensitive, PET 
imaging probes need to be developed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Imaging of neuroinflammation in dementia: a review 
Stefaniak JD, O’Brien JT 
Introduction 
Dementia is a chronic condition in which progressive cognitive impairment leads to functional 
disability. Alzheimer’s disease (AD) is the most frequent cause of dementia, but other common types 
include vascular dementia, ‘mixed’ dementia, frontotemporal dementia (FTLD), dementia with Lewy 
Bodies (DLB), and Parkinson’s Disease Dementia (PDD)[1]. Our understanding of the aetiology and 
pathogenesis of dementia is constantly increasing[2], but we are still very limited in our ability to 
accurately differentiate between dementia subtypes at early stages of the disease. This in turn limits 
our ability to give accurate diagnostic and prognostic information[3], particularly in the situation of 
overlapping phenotypes[4], and to develop treatments that prevent the progression of dementia 
when it is mild.  
As well as tau and amyloid pathology, neuroinflammation is a disease process that has been 
increasingly implicated as a pathological mechanism in dementia[5]. Unlike neurological conditions 
such as multiple sclerosis and autoimmune encephalitis in which there is an established pathogenic 
role of the adaptive immune system, neuroinflammation in dementia is thought to be mediated 
predominantly by aberrant activation of the brain’s innate immune system, namely microglia[5]. 
Microglia are CNS resident macrophages derived from haematopoietic stem cells whose processes 
rapidly converge on damaged cortex in vitro[6]. Ligands to the Peripheral Benzodiazepine Receptor 
(PBR, also known as the ‘18kDa Translocator Protein’ or ‘TSPO’) found on activated microglia amplify 
apoptosis of rat neurones in vitro[7] and delivery of microglia inhibitory factor (MIF) significantly 
reduces microglial activation and the volume of damage caused by fibrillary Abeta in aged primate 
cortex[8]. Part of the neurodegeneration in dementia might be mediated through microglial release 
of pro-inflammatory cytokines such as interleukin-1B[9].  
However, neuroinflammatory mechanisms are complex and incompletely understood, and 
neuroinflammation might also be neuroprotective in dementia under certain conditions and stages 
of the disease. It has been suggested that microgliosis in AD might initially be neuroprotective 
(through the degradation of amyloid plaques) but that impaired clearance of amyloid due to age or 
genetic predisposition leads to amyloid accumulation and an exaggerated microglial response that is 
ultimately neurodegenerative[10]. Astrocytes are the most numerous and diverse glial cells in the 
CNS and they phagocytose and degrade amyloid plaques in cultured mouse models of Alzheimer’s 
disease[11], suggesting that, as with microglial activation, reactive astrogliosis in dementia might 
initially be a protective response to the primary neuropathological insult of amyloid plaque 
formation[12]. Furthermore, in-vivo imaging of TSPO in rats after ethanol-induced neuronal insults 
suggests that activated astrocytes might limit the expansion of microglial-induced scarring[13].  
The above studies are invariably in-vitro, post-mortem or animal studies and predominantly in 
models of Alzheimer’s disease rather than other forms of dementia. The ability to measure 
neuroinflammation in humans in vivo might therefore provide novel insights into the 
neuropathology of numerous types of dementia, the development of novel preventative therapies 
as well as enabling early diagnosis and prognosis of this extremely important disease. 
Attempts have been made to measure serum and CSF biomarkers of neuroinflammation, but these 
have proven unable to provide sufficiently detailed information regarding the extent and distribution 
of neuroinflammation in vivo. Non-invasive imaging of neuroinflammation has therefore been 
heralded as a potential method of providing such information. Structural neuroimaging studies using 
e.g. CT, MRI have made limited progress to date, but functional neuroimaging technologies using e.g. 
PET[14] enable the imaging of specific molecules associated with inflammation and thus, potentially, 
detailed information regarding the neuroanatomical distribution of specific biomarkers of 
inflammation. 
Much research has therefore been done to develop technology capable of imaging 
neuroinflammation in-vivo [15]. However, efforts to develop PET ligands capable of quantifying 
regional neuroinflammation are hampered by our incomplete understanding of its pathophysiology. 
As mentioned above, the TSPO is thought to be a marker of activated microglia. It is a 
phylogenetically conserved receptor present on the outer mitochondrial membrane that has been 
implicated in cholesterol transport, cell replication and apoptosis; immunohistochemical studies 
have demonstrated minimal expression of TSPO in ependymal cells of healthy brain and significantly 
upregulated TSPO expression in microglia, macrophages and astrocytes of diseased brain[16]. Most 
of the plethora of PET ligands targeting putative inflammatory targets that have hitherto been used 
in animals or humans (see Supplementary File) have labelled the TSPO on activated microglia[16]. 
Table 1 is a summary of the techniques that have been used to image neuroinflammation in humans 
to date; whilst most target the TSPO, several ligands are available that target alternative putative 
indices of neuroinflammation including monoamine oxidase B (MAO-B) in activated astrocytes, 
peripheral macrophages that are thought to have infiltrated the CNS and even metabolite levels 
such as arachidonic acid or N-acetylaspartate that were thought to be non-specific markers of 
neuroinflammation. Increasingly, many studies have also investigated inflammatory neuroimaging in 
human dementia in vivo[17]. However, no comprehensive review has been recently published on 
this important topic.  
The authors therefore performed a systematic search of the literature for all studies that imaged 
neuroinflammation in human patients with dementia in order to investigate whether 
neuroinflammation imaging might potentially be of use in the clinical management of dementia. 
Methods 
In order to investigate the techniques used in neuroinflammation imaging, the literature was initially 
searched for studies that imaged neuroinflammation in-vivo in any neurological or psychiatric 
disorder in either humans or animal models. Thirty-three distinct imaging methodologies utilising 
PET, SPECT or MRI in either animals or humans were found and are listed in the Supplementary 
File;Table 1 contains the sixteen imaging methodologies that have been used in humans to date. 
In order to investigate the imaging of neuroinflammation in human patients with dementia, on 
7/9/2014 the databases AMED, EMBASE, HMIC, MEDLINE, PsycINFO, BNI, CINAHL, HEALTH BUSINESS 
ELITE were searched for articles with the following terms: 
((dementia OR alzheimer* OR mild cognitive impairment OR Parkinson* OR front* OR vascular) AND 
(PET OR SPECT OR imaging OR neuroimaging) AND (inflammation OR PK11195 OR DAB OR PBR OR 
TSPO OR DPA*)).af 
 There were 15,720 results that reduced to 2128 after excluding duplicates. References from this 
electronic search, as well as reference lists of reviews and important papers in the field, were 
screened on the basis of relevance of title and abstract to the review. This yielded 100 potentially 
included references. Eight of these references were only published in abstract/poster form – the 
authors of all of these references were contacted twice but only three authors replied explaining a 
full length article had not been published, so all 8 of these references were excluded because the full 
length article could not be obtained or was not yet published. After further screening on the basis of 
full text, 28 of these 92 references were included in the review and are included in Table 2. In order 
to be included, studies had to use in vivo neuroimaging of one or more markers of 
neuroinflammation on human patients with dementia, which included Mild Cognitive Impairment 
(MCI) as well as AD, vascular dementia, mixed dementia, DLB, FTLD or PDD.  
Table 1 
Ligand  Imaging Modality Mechanism of imaging neuroinflammation 
PK11195 PET, SPECT Measures TSPO 
Ro5-4864 PET Measures TSPO 
PBR28 PET Measures TSPO 
FEDAA1106 PET Measures TSPO 
DAA1106 PET Measures TSPO 
AC-5216 PET Measures TSPO 
Vincopetine PET Measures TSPO 
FEPPA PET Measures TSPO 
DEP (Deprenyl) PET Selective irreversible MAO-B antagonist that labels activated astrocytes 
DED 
(Deuteriodeprenyl) 
PET Selective irreversible MAO-B antagonist that labels activated astrocytes 
Arachidonic acid PET Neuroinflammation is characterised by phospholipase A2 activation, and 
thus arachidonic acid metabolism, in glia and neurones 
TMSX PET Measures adenosine A2A receptors (a putative regulator of 
inflammation)  
 MRS Measurement of myoinositol, N-acetylaspartate and choline 
(metabolites proposed to be elevated in neuroinflammation) 
Free-water MRI MRI A diffusion MRI processing analysis that can calculate extracellular 
volume, which is sensitive to neuroinflammation, and tissue fractional 
anisotropy, which is sensitive to axonal degeneration. Mainly images 
neuroinflammation of white matter. 
USPIO=ultra small 
particle iron oxide 
e.g. SHU555C 
MRI Labels peripheral macrophages that have infiltrated the CNS 
Gadolinium-DTPA MRI Images BBB breakdown, a putative ‘marker’ of inflammation 
Author 
(Year) 
Number of 
participants in the 
following groups: 
Imaging Ligand(s) Neuranatomical areas with significantly increased inflammation in dementia group 
relative to controls 
Other findings 
Groom 
(1995) 
Controls: 1 
AD: 8 
Small unilateral 
gliomas: 7 
[11C](R)PK11195 
[18F]FDG 
None None reported 
Cagnin 
(2001) 
Controls: 15 
AD: 8 
MCI: 1 
[11C](R)PK11195 
[18F]FDG 
Inferior and middle temporal gyri, fusiform gyri, left parahippocampal gyrus, left 
amygdala, left posterior cingulate, inferior parietal lobes, putamen and right pallidum 
in AD relative to controls. Fusiform gyri, inferior temporal gyri and left 
parahippocampus in MCI relative to controls.  
Increase inflammation in the left inferior temporal lobe discriminated AD relative to controls with a 
sensitivity of 75% and no false categorisations of controls. Areas with high inflammation showed the 
highest rate of atrophy over 12-24 months in AD. 
Versijpt  
(2003) 
Controls: 9 
AD: 10 
[123I]PK11195 
99mTc-ECD 
Prefrontal cortices, lateral frontal cortices, left orbitofrontal cortex, right mesotemporal 
cortex. 
Specific regionally increased inflammation was associated with specific cognitive impairments e.g. 
picture recognition task and right superior frontal cortex, orientation task and left lateral frontal, right 
superior frontal and left parietal cortex, verbal fluency and left parietal inferior cortex. 
Cagnin 
(2004) 
Controls: 8 
FTLD: 5 
[11C](R)PK11195 Putamen, left dorsolateral prefrontal cortex, right hippocampus, right 
parahippocampus. 
None reported 
Kropholler 
(2005) 
Controls: 6 
AD: 2 
MCI: 5 
[11C](R)PK11195 Intervention and control groups not statistically compared in article for this purpose None reported 
Anderson  
(2007) 
Controls: 12 
AD: 4 
Huntington’s: 11 
[11C](R)PK11195 Intervention and control groups not statistically compared in article for this purpose None reported 
Kropholler 
(2007) 
Controls: 20 
AD: 9 
MCI: 10 
[11C](R)PK11195 None None reported 
Schuitema
ker 
(2007) 
Controls: 20 
AD: 9 
[11C](R)PK11195 Intervention and control groups not statistically compared in article for this purpose None reported 
Turkheime
r 
(2007) 
Controls: 18 
AD: 4 
Huntington’s: 3 
[11C](R)PK11195 Intervention and control groups not statistically compared in article for this purpose None reported 
Boellaard 
(2008) 
Controls: 9 
AD: 9 
[11C](R)PK11195 Intervention and control groups not statistically compared in article for this purpose None reported 
Edison 
(2008) 
Controls: 24 
AD: 13 
[11C](R)PK11195 
[11C]PIB 
Frontal, temporal, parietal, occipital and cingulate cortices. Inflammation in posterior cingulate gyri, parietal cortices and frontal cortices correlated with MMSE 
scores. Inflammation did not correlate with PiB binding. 
Esposito 
(2008) 
Controls: 9 
AD: 8 
[1-11C]AA 
[15O]water 
78 of 90 hemispheric grey-matter regions widespread in the neocortex, hippocampus 
and amygdala. The only regions without increased inflammation were the caudate, 
pallidum, posterior cingulate, right anterior and middle cingulate, left superior occipital 
cortex, left superior and medial temporal poles and left thalamus i.e. mainly 
subcortical.  
None reported 
Tomasi  
(2008) 
Controls: 10 
AD: 10 
[11C](R)PK11195 Cerebellum, lateral occipital lobe, anterior cingulate gyrus, posterior cingulate gyrus, 
frontal lobe middle frontal gyrus, posterior temporal lobe, parietal lobe, thalamus, 
superior parietal gyrus and occipital lobe lingual gyrus. 
None reported 
Yasuno 
(2008) 
Controls: 10 
AD: 10 
[11C]DAA1106  Dorsal and medial prefrontal cortices, lateral temporal cortices, parietal cortices, 
occipital cortices, anterior cingulate cortices, striatum and cerebellum. 
No correlation between MMSE and inflammation in any volume of interest. 
Table 2 
 
Okello 
(2009) 
Controls: 24 
AD: 22 
Amnestic MCI: 14 
[11C](R)PK11195 
[11C]PIB 
11C-PiB positive MCI patients had increased inflammation in frontal cortices relative to 
controls. Data not given for inflammation in AD relative to controls. 
No correlation between regional inflammation and PiB in MCI. No correlation between age of onset or 
MMSE score and inflammation in AD-PiB positive patients. Correlation between lower MMSE and 
increased inflammation in the anterior cingulate and temporal cortices in AD-PiB negative patients. 
Wiley 
(2009) 
Controls: 5 
AD: 6 
MCI: 6 
[11C](R)PK11195 
[11C]PIB 
None No difference in inflammation between PiB positive or negative patients. 
Gulyas 
(2011) 
Controls: 12 
AD: 6 
[11C]-vincopetine None None reported 
Santillo  
(2011) 
Controls: 11 
AD: 9 
11C-DED [11C]PIB Frontal, parietal, temporal and medial temporal lobes. Correlation between inflammation and PiB binding in occipital cortex. 
Yokokura 
(2011) 
Controls: 10 
AD: 11 
[11C](R)PK11195 
[11C]PIB [18F]FDG 
Medial frontal and parietal cortices and left temporal cortex. Negative correlation between MMSE and inflammation in the left anterior cingulate cortex, left 
precuneus, left hippocampus and left middle frontal cortex. Negative correlation between 
inflammation and PiB binding in posterior cingulate cortices. 
Carter 
(2012) 
Controls: 14 
AD: 7 
MCI: 8 
11C-DED [11C]PIB 
18F-FDG 
Frontal and parietal cortices in MCI relative to controls. Right occipital cortex in MCI 
PiB+ patients relative to controls/MCI PiB- patients/AD. 
Decreased inflammation in right hippocampus in AD relative to MCI and controls.  
No regional correlation between the 3 PET tracers. 
Yaqub 
(2012) 
Controls: 17 
AD: 8 
MCI: 9 
[11C](R)PK11195 None None reported 
Yasuno 
(2012) 
Controls: 10 
AD: 10 
MCI: 7 
[11C]DAA1106  Cerebellum, medial prefrontal cortices, parietal cortices, lateral temporal cortices, 
anterior cingulate cortices and striatum in MCI and AD relative to controls. No regional 
difference between MCI and AD. 
No correlation between MMSE and regional inflammation. MCI patients with global inflammation 0.5 
standard deviations greater than the control mean developed dementia within 5 years (75% AD, 25% 
DLB). 
Edison 
(2013) 
Controls: 24 
PDD: 11 
Parkinson’s: 8 
[11C](R)PK11195 
[11C]PIB [18F]FDG 
Anterior and posterior cingulate, frontal, temporal, parietal, occipital cortices and 
striatum in PDD relative to controls. 
Negative correlation between inflammation and MMSE in tempero-parietal, occipital and frontal 
cortices. 
Iannaccon
e (2013) 
Controls: 11 
DLB: 6 
Parkinson’s: 6 
[11C](R)PK11195 Basal ganglia, substantia nigra, frontal lateral cortices, parietal lateral cortices, 
temporal lateral cortices, anterior and posterior cingulate cortices, occipital medial 
cortices, occipital lateral cortices, temporal poles and precuneus in DLB relative to 
controls. 
None reported 
Kreisl 
(2013) 
Controls: 13 
AD: 19 
MCI: 10 
[11C]PBR28 
[11C]PIB 
Prefrontal cortices, sensorimotor cortices, inferior parietal cortices, superior parietal 
cortices, middle and inferior temporal cortices, posterior cingulate cortices, occipital 
cortices, hippocampi and entorhinal cortices in AD relative to controls. Differences 
were greatest in inferior parietal lobules, middle and inferior temporal cortices and 
precuneus, but no difference was seen in white matter, thalamus, striatum or 
cerebellum. No difference in inflammation in any region between MCI and controls. 
MMSE, Clinical Dementia Rating Scale Sum of Boxes, Logical Memory Intermediate (Wechsler Memory 
Scale Third Edition), Trail Making part B and Block Design (Wechsler Adult Intelligence Scale Third 
Edition) scores negatively correlated with inflammation, particularly in inferior parietal lobules, in MCI 
and AD. Inflammation in parietal cortex and striatum negatively correlated with age of onset in MCI 
and AD. Correlation between inflammation and PiB in inferior parietal lobules, superior temporal 
cortices, precuneus, hippocampi and parahippocampal gyri, in AD and MCI, after partial volume 
correction. 
Schuitema
ker  
(2013) 
Controls: 21 
AD: 19 
MCI: 10 
[11C](R)PK11195 Voxel-wise statistical parametric mapping showed small clusters of increased 
inflammation in occipital lobes in AD relative to controls. Region of interest analysis 
showed no significant differences in inflammation between groups (including between 
MCI and control patients). 
No significant difference in regional inflammation between MCI patients who progressed to dementia 
and MCI patients who did not. Inflammation did not correlate with MMSE, New York University 
paragraph recall test, Rey’s Auditory Verbal Learning Test or Trail A and B tests.  
Varrone 
(2013) 
Controls: 7 
AD: 9 
[18F]FEDAA1106 None None reported 
Yoder 
(2013) 
Controls: 18 
AD: 7 
MCI: 7 
[11C]PBR28 Intervention and control groups not statistically compared in article for this purpose PBR28 binding is sensitive to TSPO genotype. 
Results 
After screening on the basis of full text, 28 studies (see Table 2) were considered to meet the 
inclusion criteria and used in vivo neuroimaging of one or more markers of neuroinflammation on 
human patients with dementia, which was taken to include MCI as well as Alzheimer’s disease, 
vascular dementia, mixed dementia, Lewy body dementia, frontotemporal dementia or Parkinson’s 
Disease Dementia.  
Twenty-seven of these studies used PET and only one study[18] used SPECT as the imaging modality 
to measure neuroinflammation.  
Seven ligands were used; 19 studies used PK11195[18-36], two studies used DAA1106[37-38], one 
study used vincopetine[39], two studies used DED[40-41], two studies used PBR28[42-43], one study 
used FEDAA1106[44] and one study used arachidonic acid (AA)[45]. Five of these seven ligands 
(PK11195, DAA1106, vincopetine, PBR28, FEDAA1106) bind the TSPO on activated microglia, one 
(DED) binds to MAO-B in activated astrocytes and one (AA) images a metabolic by-product of 
microglial-induced neuroinflammation[45]. No study was found that used two ligands together to 
measure neuroinflammation.  
The mean number of control participants was 13.1 (range 1-24) and the mean number of 
participants in a dementia group was 8.9 (range 1-22). 
All 28 studies had a cross-sectional design to at least part of the trial; 25 of the 28 studies were 
purely cross-sectional whilst one study had both cross-sectional and case-control components[20] 
and two studies had both cross-sectional and cohort components[36, 38].  
All 28 studies included healthy control participants while 14 studies had comparator groups with 
Alzheimer’s disease[18-19, 23, 25-29, 32, 37, 39-40, 44-45], 11 studies had both Alzheimer’s disease 
and MCI comparator groups[20, 22, 24, 30, 31, 33, 36, 38, 41, 42, 43], one study had FTLD as the 
comparator[21], one study had PDD[34] and one had DLB[35]. Six of the 28 included studies 
investigated neuroimaging methodologies and did not compare inflammatory ligand binding 
between dementia and control patients[22, 23, 25-27, 43]; their results are thus not pertinent to the 
question of whether inflammation neuroimaging might potentially be of use in the clinical treatment 
of dementia. The present review therefore found 22 studies which compared inflammatory ligand 
binding (and thus neuroinflammation) between control and dementia patients. A minority (6) of 
these 22 studies did not find a statistically significant difference in inflammation between control 
and dementia patients in at least one region of the brain[19, 24, 31, 33, 39, 44]; each of these 6 
‘negative’ cross-sectional studies compared control patients with Alzheimer’s disease +/- MCI 
patients, therefore no ‘negative’ cross-sectional studies were found that investigated other 
dementia subtypes. The majority (16) of the 22 included studies which compared 
neuroinflammation between control and dementia patients found a statistically significant 
difference in inflammation between control and dementia patients in at least one brain region[18, 
20, 21, 28, 29, 30, 32, 34-38, 40, 41, 42, 45].  Unexpectedly, one of these 16 cross-sectional studies 
reported decreased inflammation in the right hippocampus in AD relative to controls[41], but the 
remainder found increased neuroinflammation in dementia patients.  
Nine included studies compared MCI with healthy age-matched controls[20, 24, 30, 31, 33, 36, 38, 
41, 42]. Three of these studies[24, 31, 33] found no statistically significant difference in 
neuroinflammation in AD or MCI relative to age-matched controls, two of these studies found 
increased neuroinflammation in AD (but not MCI) relative to controls[36, 42], two of these studies 
found increased neuroinflammation in AD and MCI relative to controls[20, 38], one study found 
increased neuroinflammation in MCI relative to controls but did not give data for AD relative to MCI 
or controls[30] and one study found increased neuroinflammation in MCI relative to both AD and 
controls[41]. 
One study[20] used discriminant function analysis to show, retrospectively, that increased 
inflammation in the left inferior temporal lobe discriminated AD patients from age-matched controls 
with a sensitivity of 75% and with no false categorisations of controls.  
One study[20] found that neuroanatomical regions with high inflammation demonstrated the 
highest rate of atrophy over 1-2 years, whilst Yasuno et al (2012)[38] found that 4 out of the 5 MCI 
patients who were followed up had whole measured region neuroinflammation more than 0.5 
standard deviations greater than the control mean and all 4 developed dementia within 5 years. 
However, Schuitemaker et al (2013)[36] did not find significant differences in neuroinflammation 
between MCI patients who progressed to dementia and MCI patients who did not. 
Several of the included studies investigated whether regional neuroinflammation correlated with 
dementia severity, as measured by either cognition[18, 28, 30, 32, 34, 36-38, 42] or age of dementia 
onset[30, 42]. Three of these studies found no statistically significant association between MMSE 
and ligand binding in any neuroanatomical region in Alzheimer’s disease[36-38]. Five studies found 
statistically significant correlations between standardised cognitive questionnaire scores and 
regional neuroinflammation in Alzheimer’s disease[18, 28, 30, 32, 42]. The neuroanatomical regions 
demonstrating an association between inflammation and cognition varied between studies but 
included frontal cortex[18, 28, 32], parietal cortex[18, 28, 42], temporal cortex[30], cingulate 
cortex[28, 30, 32], precuneus[32] and hippocampus [32]. Furthermore, one study found a 
statistically significant association between cognition and neuroinflammation in the frontal, parietal, 
temporal and occipital cortex in Parkinson’s Disease Dementia[34]. No studies were found by this 
review investigating an association between cognition and neuroinflammation in any other 
dementia type.  
Only two studies assessed whether regional neuroinflammation correlated with age of dementia 
onset in Alzheimer’s disease. Okello et al (2009)[30] found no correlation between duration of 
symptoms and neuroinflammation in AD patients who were amyloid positive, whilst Kreisl et al 
(2013)[42] found that early onset (<65) AD patients had increased global neuroinflammation relative 
to late-onset (>65) AD patients. Kreisl et al (2013)[42] also found that neuroinflammation in the 
parietal cortex and striatum correlated with lower age of dementia onset in AD patients.  
Seven studies were found that used multiple PET ligands to image not just neuroinflammation but 
also amyloid load (e.g. Pittsburgh Compound B [PiB] binding). Four of these seven studies found no 
statistically significant correlation between inflammatory ligand binding and PiB binding in 
Alzheimer’s disease[28, 30, 31, 41]. Three of these seven studies[32, 40, 42] found inflammatory 
ligand binding to positively correlate with PiB binding (and thus, presumably, amyloid load) in at 
least one neuroanatomical region (the parietal cortex[42], temporal cortex[42], occipital cortex [40], 
cingulate cortex[32], hippocampus[42] and precuneus[42]) in Alzheimer’s disease.   
Discussion 
The present review contributes to the existing literature on neuroinflammation imaging, and thus is 
of interest not just for dementia but also for the diverse and increasing number of disorders that 
have a putative inflammatory component; this includes depression[46], delirium[47] and 
schizophrenia[48]. 
The majority of the studies to date of in vivo imaging of neuroinflammation in dementia have used 
PET imaging of the TSPO microglial marker. TSPO is an attractive imaging target because if it were 
found to be correlated with the development of dementia in vivo it would be relatively simpler to 
attempt to modify this single molecular target than if multiple separate markers of 
neuroinflammation were each shown to be partly involved. However, the almost exclusive focus on 
TSPO is a weakness within the current imaging literature since microglial activation is unlikely to 
represent the totality of the neuroinflammatory response in dementia. Indeed, astrocytes have been 
implicated in the neuroinflammation of dementia[5] but only two[40,41] of the twenty-eight studies 
included in the present review used radioligands targeting a putative marker of astrocyte activation, 
namely MAO-B. Whilst the majority of PET ligands found to have been used in the imaging of 
neuroinflammation in any neuropsychiatric disorder in humans also target the TSPO (see Table 1), 
ligands are available from animal studies that target alternative putative indices of 
neuroinflammation e.g. COX-1, MPO, macrophage infiltration and even metabolite levels such as 
arachidonic acid or N-acetylaspartate (see Supplementary File). Future studies should therefore 
investigate the utility of such alternative ligands, either in isolation or in combination with TSPO-
targeting ligands, in dementia patients. 
An additional cause for concern by the current focus on TSPO imaging in the literature is the finding 
that the rs6971 TSPO single nucleotide polymorphism alters binding affinity of second generation 
radioligands for TSPO between healthy individuals independently of the degree of inflammation. 
Indeed, in vivo uptake in healthy individuals of the PBR28 radioligand for TSPO was 40% greater in 
homozygotes than heterozygotes for the high affinity TSPO protein [49]. However, only one[43] of 
the six[37-39,42-44] studies using second generation TSPO radioligands that were included in the 
present review measured participant TSPO binding affinity genotype. Furthermore, a possible role 
for the rs6971 TSPO single nucleotide polymorphism as a modifier of neuroinflammation in 
dementia has not been extensively investigated, despite in vitro evidence that high affinity rs6971 
TSPO homozygotes have significantly elevated levels of the neurosteroid precursor, pregnenolone, in 
peripheral cells compared to low affinity homozygotes or heterozygotes[50]. It is therefore 
imperative that future imaging studies control for the relative proportions of low and high affinity 
TSPO participants[43]. 
Whilst a minority of the included studies did not find a statistically significant difference in 
inflammation between control and dementia patients in at least one region of the brain[19, 24, 31, 
33, 39, 44], the studies included in this review were not adequately powered to conclude that there 
is no significant difference in neuroinflammation between dementia and controls.  Furthermore, the 
majority (15) of included studies found increased neuroinflammation in at least one 
neuroanatomical region in dementia patients relative to controls. Alzheimer’s disease was the most 
commonly studied dementia type, with increased inflammation in virtually all neuroanatomical 
locations, both cortical 
(frontal/parietal/temporal/occipital/cingulated/hippocampal/entorhinal/fusiform 
gyri/parahippocampal gyri) and subcortical (amygdala, pallidum, thalamus, striatum). There were 
significant differences between trials in the anatomical structures (and their laterality) demonstrated 
to have increased inflammation; comparison of results between studies was not helped by the 
frequent use of different neuroanatomical ‘regions of interest’ between studies. Thus, whilst the 
majority of studies investigating neuroinflammation imaging in Alzheimer’s disease demonstrated 
increased neuroinflammation relative to controls, it is not possible to state with certainty the 
neuroanatomical location where such increased neuroinflammation occurs. This is in contrast with 
e.g. FDG-PET imaging studies demonstrating reproducible reductions in glucose metabolism in 
frontal, parietal, temporal and posterior cingulate cortices of Alzheimer’s disease patients[51] and 
suggests either that existing imaging studies do not accurately portray the distribution of 
neuroinflammation in vivo or that neuroinflammation is globally increased in Alzheimer’s disease. 
Furthermore, if neuroinflammation is globally increased in Alzheimer’s disease this might suggest 
that neuroinflammation does not contribute to the early stages of its disease pathogenesis, since 
early Alzheimer’s disease typically involves preferential atrophy of the temporal cortex and 
hippocampus[4]. Only three studies were found  that investigated non-Alzheimer’s types of 
dementia (FTLD[21], PDD[34] and DLB[35]), but all three, similarly to the findings in Alzheimer’s 
disease, found increased neuroinflammation in a variety of cortical and subcortical structures. 
Therefore a plethora of neuroanatomical structures have been implicated as having increased 
neuroinflammation in all dementias studied, but the published evidence to date does not indicate 
whether the regional distribution of neuroinflammation differs between dementia types or even 
whether it is reproducible within a single dementia type between individuals. It also raises the 
tantalising possibility that neuroinflammation might be a common pathological mechanism in all 
types of dementia.  
Nine included studies compared MCI patients with healthy controls[20, 24, 30, 31, 33, 36, 38, 41, 
42]. Taken together, the results of these 9 studies are equivocal; five of these studies found no 
statistically significant difference in neuroinflammation in MCI relative to control patients[24, 31, 33, 
36, 42] whilst 4 of these studies found increased neuroinflammation in MCI relative to controls in 
frontal cortices[38, 30, 41], parietal cortices[38, 41], temporal cortices[20, 38], anterior cingulate 
cortices[38], fusiform gyri[20], left parahippocampus[20], striatum[38] and cerebellum[38]. Thus, it 
is less clear that neuroinflammation is increased relative to controls in MCI than it is for dementia, 
and therefore it is unclear whether neuroinflammation is part of the pathogenesis in early stages of 
dementia. However, the regional distribution of any neuroinflammation that might occur appears to 
be similar to that in dementia i.e. in a variety of cortical and subcortical structures. 
Multi-tracer PET studies included in this review found only an inconsistent and weak correlation 
between neuroinflammation and other, better established markers of Alzheimer’s disease load (such 
as PiB). This suggests that neuroinflammation imaging might highlight novel aspects of dementia not 
revealed by existing neuroimaging ligands and therefore be more useful in the clinical management 
of dementia than existing neuroimaging methods have proven to be. Indeed, several of the included 
studies attempted to investigate neuroinflammation imaging for potential clinical management 
purposes in dementia. One study[20] found, retrospectively, that increased neuroinflammation in 
the left inferior temporal lobe distinguished AD patients from controls with no false categorisations 
of controls and a sensitivity of 75%; further studies are now needed that prospectively trial the use 
of neuroinflammation imaging as a diagnostic tool in early stages of dementia, including MCI, when 
a clinical diagnosis is difficult to make. Furthermore, three of the included studies investigated 
whether neuroinflammation was prognostic in Alzheimer’s disease[20, 36, 38]; Cagnin et al 
(2001)[20] found that neuroanatomical regions with high inflammation demonstrated the highest 
rate of atrophy over 1-2 years, whilst Yasuno et al (2012)[38] found that 4 out of the 5 MCI patients 
who were followed up had whole measured region neuroinflammation more than 0.5 standard 
deviations greater than the control mean and all 4 developed dementia within 5 years. However, 
Schuitemaker et al (2013)[36] did not find significant differences in neuroinflammation between MCI 
patients who progressed to dementia and MCI patients who did not; further research is therefore 
needed before deciding whether neuroinflammation imaging might potentially be used as a 
prognostic tool in the clinical management of dementia. Similarly, several of the included studies 
attempted to correlate neuroinflammation with dementia severity, as measured by either 
standardised cognition questionnaire scores or age of onset. The results were mixed and not 
convincingly reproducible; 3 studies found no association between cognition and regional 
neuroinflammation in Alzheimer’s disease[36-38], five studies found significant correlations between 
cognition and regional neuroinflammation in Alzheimer’s disease[18, 28, 30, 32, 42], one study 
found a statistically significant association between cognition and neuroinflammation in Parkinson’s 
Disease Dementia[34], one study found no correlation between age of onset and neuroinflammation 
in AD[30] whilst one study found that neuroinflammation in the parietal cortex and striatum 
correlated with earlier disease onset in AD[42]. Therefore the existing literature does not 
unequivocally demonstrate that neuroinflammation is an objective correlate of dementia severity in 
vivo. 
Despite its great potential, the lack of reproducibility of positive findings in this review therefore 
demonstrates that neuroinflammation imaging has not thus far been convincingly used for diagnosis, 
prognosis or severity profiling in any dementia subtype. The observed heterogeneity of results 
between studies of the same type of dementia (Alzheimer’s disease) is likely due to multifactorial 
causes that include greater variability in the pathogenesis of neuroinflammation than is currently 
understood; since different inflammatory mechanisms might be responsible for different phases of 
neuroinflammation in dementia, it is not entirely unsurprising that a single imaging modality 
detecting one aspect of neuroinflammation (such as microglial activation in the case of the PK11195 
ligand) might be unable to detect similar differences between Alzheimer’s disease patients at 
different stages of the disease. Furthermore, existing studies have generally been small and 
inadequately powered, and whilst PK11195 is a robust marker of neuroinflammation its small signal-
to-noise ratio might make it unable to detect subtler patterns of regional neuroinflammation that 
might exist in dementia. In order to further investigate the role of neuroinflammation imaging in the 
clinical management of dementia, adequately powered trials are therefore needed which take into 
account the stage of dementia, patient TSPO genotype and use more sensitive TSPO imaging ligands, 
ideally in conjunction with alternative markers of neuroinflammation.  
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